CRISPR-based therapeutic approaches for neurodegenerative diseases

Based on my research into CRISPR-based therapeutic approaches for neurodegenerative diseases, I'll present 7 novel therapeutic hypotheses that build upon current evidence while proposing innovative mechanisms and targets. ## 1. **Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation** **Description:** Deploy CRISPR interference (CRISPRi) to selectively downregulate MSH3 and PMS1 expression specifically during neuronal maturation phases, creating temporal windows of CAG repeat stability in Huntington's disease. This approach leverages the discovery that these mismatch repair proteins drive somatic expansion of HTT CAG repeats. **Target gene/protein:** MSH3, PMS1 (DNA mismatch repair components) **Supporting evidence:** Recent studies demonstrate that MSH3 suppression reduces somatic CAG repeat expansion in HD models (PMID:38609352). CRISPR-Cas9 in vivo screening identified genetic modifiers of CAG instability, confirming mismatch repair as a therapeutic target (PMID:39843658). The temporal nature of CAG expansion suggests developmental windows where intervention could be most effective. **Predicted outcomes:** 30-50% reduction in somatic CAG expansion, delayed onset by 5-10 years in HD patients, improved motor function preservation. **Confidence:** 0.75 ## 2. **Prime Editing Precision Correction of APOE4 to APOE3 in Microglia** **Description:** Utilize optimized prime editing systems with microglia-targeted AAV delivery to convert the disease-associated APOE4 C130R mutation to protective APOE3 variant. This approach targets the primary cell type responsible for APOE production in the brain while avoiding systemic effects. **Target gene/protein:** APOE (apolipoprotein E) **Supporting evidence:** Prime editing has been successfully optimized for APOE4 correction with improved efficiency and reduced off-target effects (PMID:39642875). Microglia are the primary source of brain APOE and key drivers of Alzheimer's pathology. CRISPR-based APOE4 correction strategies are actively being developed with novel delivery approaches (PMID:41812941). **Predicted outcomes:** 60-80% conversion efficiency in targeted microglia, reduced amyloid plaque burden, improved cognitive outcomes in APOE4 carriers. **Confidence:** 0.80 ## 3. **Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms** **Description:** Deploy acid-degradable lipid nanoparticles (ADP-LNPs) for in utero intracerebroventricular delivery of base editors to correct dominant mutations in severe early-onset neurodegenerative diseases like childhood ALS or early Huntington's disease, targeting the developmental window before irreversible damage occurs. **Target gene/protein:** SOD1, HTT, TARDBP (depending on specific mutation) **Supporting evidence:** ADP-LNPs achieve 30% transfection efficiency in fetal brain cells with no developmental toxicity (PMID:39445691). In utero gene editing provides access to neural progenitors before differentiation. Prime editing enables precise correction without double-strand breaks (PMID:33097693). **Predicted outcomes:** Prevention of disease onset, normal neurodevelopment, 70-90% correction in targeted neural populations. **Confidence:** 0.65 ## 4. **Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation** **Description:** Engineer multiplexed cytosine base editors coupled with CRISPRa to simultaneously correct disease-causing mutations while upregulating endogenous neuroprotective factors (BDNF, GDNF, IGF-1) in the same cells. This creates a dual therapeutic effect of mutation correction plus enhanced neuronal resilience. **Target gene/protein:** Disease gene (SOD1, TARDBP) + neuroprotective genes (BDNF, GDNF, IGF-1) **Supporting evidence:** Base editing can achieve high-efficiency single nucleotide corrections without double-strand breaks. CRISPRa can robustly activate endogenous gene expression. Multiplexed approaches have been demonstrated in other disease contexts. Neuroprotective factors show therapeutic benefit in preclinical neurodegenerative models. **Predicted outcomes:** 50-70% mutation correction plus 3-5 fold upregulation of neuroprotective factors, synergistic therapeutic benefit exceeding single interventions. **Confidence:** 0.70 ## 5. **CRISPR-Mediated Mitochondrial Genome Editing for Complex I Dysfunction** **Description:** Develop mitochondria-targeting CRISPR systems (mitoCas) to correct mtDNA mutations associated with complex I deficiency in Parkinson's disease and ALS. Use peptide-guided delivery to specifically target damaged mitochondria while preserving healthy organelles. **Target gene/protein:** MT-ND1, MT-ND4, MT-ND6 (mitochondrial complex I subunits) **Supporting evidence:** Mitochondrial dysfunction is central to Parkinson's and ALS pathogenesis. Complex I defects are found in substantia nigra neurons. Mitochondria-targeting CRISPR systems are being developed for mtDNA editing. CRISPR t [...]